He is the clinical Chief of the Thoracic Surgery Service of the HUMT and has been put forward his task of reviewing and promoting a universal staging system for patients with lung cancer.
News
Dr. Rami-Porta, recognized with the utmost distinction by the International Association for the Study of Lung Cancer
Dr. Ramon Rami-Porta, Clinical chief of the Thoracic Surgery Service at MútuaTerrassa University Hospital, has been distinguished by the International Association for the Study of Lung Cancer (IASLC) at the 18th edition of the World Conference on Lung Cancer. It is celebrating these days in Yokohama (Japan). He has been granted the highest distinction - the so-called Merit Award - for its effort and commitment to the development of a unified and internationally recognized staging system for decision making in the treatment of patients with lung cancer.
This recognition is granted only to some members of IASLC who have contributed in an extraordinary way to the development of the association. In this sense, it is the first Merit Award that distinguishes a professional from Spain. The award was received during the opening ceremony of the congress, held on Sunday October 15, at which time it was also announced that he will be the president of the World Conference on Lung Cancer to be held in Barcelona in 2019.
Chairman of the IASLC International Statistical and Factors Committee until 2016, Dr. Rami has been a member of this association since 1990. In the words of Dr. Fred R. Hirsch, Executive Director of IASLC, "Statistically Correct is crucial to offer patients appropriate treatment and for this reason it is a great honor for IASLC to recognize Dr. Rami-Puerta for the accomplishment of this monumental task. "
Dr. Rami-Porta has led from the HUMT the latest revision of a new tool to define the prognosis of lung cancer that has been used in every hospital in the world since the beginning of the year. It is the so-called 8th edition of the TNM classification of lung cancer, the objectives are to improve the classification of the anatomical extension of this neoplasia, contribute to fine-tuning prognosis and help to stratify tumors in future clinical trials. The innovations introduced in this 8th edition are based on analyzes performed on more than 70,000 patients with non-small cell lung cancer and 6,100 patients with small cell lung cancer.
